Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
about
Interferon alpha for the adjuvant treatment of cutaneous melanomaChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cellsDacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)Malignant melanoma (non-metastatic).Utility of adjuvant systemic therapy in melanoma.Interferon-alpha therapy for melanoma.Adjuvant therapy in melanoma.Sentinel node biopsy: who needs it?IL28B polymorphism cannot predict response to interferon alpha treatment in patients with melanoma.An update on adjuvant interferon for melanoma.Cytokine therapy in dermatology.Adjuvant therapy for high-risk primary and resected metastatic melanoma.Systematic review of medical treatment in melanoma: current status and future prospects.The relation between c-myc expression and interferon sensitivity in uveal melanoma.Diagnosis and treatment of cutaneous melanoma: a practical guide.Adjuvant therapy: melanomaNovel dendritic cell-based vaccination in late stage melanomaManagement of psychiatric adverse events with immunotherapy with interferon-alfa.A review of evidence-based treatment of stage IIB to stage IV melanoma.Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.SEOM guidelines for the management of Malignant Melanoma 2015Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesionsBiochemotherapy of metastatic malignant melanoma. Predictive value of tumour-infiltrating lymphocytes.Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.Malignant melanoma of the anal region.Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patientsAdjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approachAdjuvant therapy of melanoma with interferon: lessons of the past decadeAdjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?Novel therapeutics for melanoma.Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.Role of bacillus Calmette-Guérin in the treatment of advanced melanoma.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Advances in cutaneous melanoma.An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review.Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon.Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.Cost-effectiveness of therapies for melanoma.
P2860
Q24201908-D413CD50-AA38-4C50-B1A6-0835F3153B66Q26770492-5307BAA0-0F7B-4264-BDCC-7EA733233383Q28343494-3C2BBDD5-19C9-4590-8FE7-A7350C011B8FQ28362951-501F45AC-9264-47CD-AC95-050DC53E82A3Q33448157-BB1D9488-7107-4AFC-A3E9-DBEF09320B8BQ33484065-CE09D7A4-0179-45AE-BE87-4B697CC3BD5FQ33836075-CA055F25-CB22-4B3B-9A28-0199F4985572Q34067633-E5DADAFE-0683-456B-97EF-36D363F64EE4Q34109275-0D0E522C-2ED8-491A-8327-AE75A50D4694Q34497983-AD51ECCB-4800-4FE5-B80A-6537A004CE79Q34573032-D6F366A5-8BB8-45A0-BF6C-1874333036BCQ34626999-C9279A73-5C90-4900-B41B-003B1C802044Q35048323-86FF3512-D0F5-4BCF-861E-564DC9A6B852Q35584299-F988B2C1-FA80-4B32-9B16-AFA28E87AF8AQ35592697-2090C7B5-1F2E-435E-89BF-882449F0E36FQ35606955-47C71686-B639-4CE8-B28A-6A9B96B81483Q35636225-41109E2C-9431-49CC-BD85-817F4E1E3735Q35886439-88AB389A-C4E5-491F-8BCE-7345F96F9BE6Q35956876-D2677D24-649B-4069-BA70-6412167BBB39Q36229746-FEBD1678-4E69-40F1-B21F-C4115E73014AQ36365458-4F32D2C0-B0FB-46B1-84A7-7CA0ACFEB44CQ36400221-174324EB-8A8B-40A9-99D4-A9069FC7BDD7Q36438350-4310E49C-F675-4D7C-85AD-00A305EE32F1Q36623326-2F300322-7768-48AB-B427-FACE029399F0Q36691820-4AC45B26-8A7F-4D84-9EC3-4937CEBEF6CAQ36765872-E10022B6-BC35-45B6-BF06-0A30E96A7003Q36779843-A9FB230E-3634-4781-944D-D2A7047389ACQ36844314-CC5141D9-9B98-4CDD-8D82-24EB37141C76Q37021067-C8224082-0282-4700-8148-59ADB85674BEQ37225766-38A33131-84AA-46AA-BEF2-B4E815E428CAQ37508041-C10A09D7-830C-49E9-874D-1E9E8E3B760CQ37641495-4664B700-AC7F-4132-B02C-F80B8187B66EQ37952235-91F2F5B8-0F89-426B-8C67-DAD9749029D8Q37952804-51D5E127-AE48-4DCE-B35C-51C58EEC0826Q38007036-5265A476-8D10-43EF-B7D9-F7BCB6246012Q38068207-B840BB79-CF19-4EE3-BC99-6B6DAD4C1B2FQ38151728-827CDED9-803F-4346-8775-707E5AF2B6D3Q38195330-2748E5F6-4BAF-4328-8AD7-9AAB18D1C6E7Q38242004-831834D5-15CA-4140-8A2A-C863DE59CE21Q38363756-009DAB7C-7DF5-4EF7-A5E4-782C269B8093
P2860
Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Randomised trial of interferon ...... Cooperative Group on Melanoma.
@en
Randomised trial of interferon ...... Cooperative Group on Melanoma.
@nl
type
label
Randomised trial of interferon ...... Cooperative Group on Melanoma.
@en
Randomised trial of interferon ...... Cooperative Group on Melanoma.
@nl
prefLabel
Randomised trial of interferon ...... Cooperative Group on Melanoma.
@en
Randomised trial of interferon ...... Cooperative Group on Melanoma.
@nl
P2093
P1433
P1476
Randomised trial of interferon ...... Cooperative Group on Melanoma.
@en
P2093
B Sassolas
C Chastang
D Cupissol
J J Bonerandi
J P Cesarini
M Delaunay
P Souteyrand
P304
P356
10.1016/S0140-6736(97)12445-X
P407
P577
1998-06-01T00:00:00Z